These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 27552991)

  • 41. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities.
    Zhang J; Lieu YK; Ali AM; Penson A; Reggio KS; Rabadan R; Raza A; Mukherjee S; Manley JL
    Proc Natl Acad Sci U S A; 2015 Aug; 112(34):E4726-34. PubMed ID: 26261309
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes.
    Madan V; Li J; Zhou S; Teoh WW; Han L; Meggendorfer M; Malcovati L; Cazzola M; Ogawa S; Haferlach T; Yang H; Koeffler HP
    Am J Hematol; 2020 Feb; 95(2):133-143. PubMed ID: 31680297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comprehensive analysis of RNA-binding protein SRSF2-dependent alternative splicing signature in malignant proliferation of colorectal carcinoma.
    Liu W; Li D; Lu T; Zhang H; Chen Z; Ruan Q; Zheng Z; Chen L; Guo J
    J Biol Chem; 2023 Feb; 299(2):102876. PubMed ID: 36623729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SRSF2 Regulates Alternative Splicing to Drive Hepatocellular Carcinoma Development.
    Luo C; Cheng Y; Liu Y; Chen L; Liu L; Wei N; Xie Z; Wu W; Feng Y
    Cancer Res; 2017 Mar; 77(5):1168-1178. PubMed ID: 28082404
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
    McFarlane M; MacDonald AI; Stevenson A; Graham SV
    J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Splicing Factor Mutations in Cancer.
    Bejar R
    Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Splicing factor mutant myelodysplastic syndromes: Recent advances.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2020 Jan; 75():100655. PubMed ID: 31558432
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes.
    Nguyen HD; Leong WY; Li W; Reddy PNG; Sullivan JD; Walter MJ; Zou L; Graubert TA
    Cancer Res; 2018 Sep; 78(18):5363-5374. PubMed ID: 30054334
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome.
    Colla S; Ong DS; Ogoti Y; Marchesini M; Mistry NA; Clise-Dwyer K; Ang SA; Storti P; Viale A; Giuliani N; Ruisaard K; Ganan Gomez I; Bristow CA; Estecio M; Weksberg DC; Ho YW; Hu B; Genovese G; Pettazzoni P; Multani AS; Jiang S; Hua S; Ryan MC; Carugo A; Nezi L; Wei Y; Yang H; D'Anca M; Zhang L; Gaddis S; Gong T; Horner JW; Heffernan TP; Jones P; Cooper LJ; Liang H; Kantarjian H; Wang YA; Chin L; Bueso-Ramos C; Garcia-Manero G; DePinho RA
    Cancer Cell; 2015 May; 27(5):644-57. PubMed ID: 25965571
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SRSF2 plays an unexpected role as reader of m
    Ma HL; Bizet M; Soares Da Costa C; Murisier F; de Bony EJ; Wang MK; Yoshimi A; Lin KT; Riching KM; Wang X; Beckman JI; Arya S; Droin N; Calonne E; Hassabi B; Zhang QY; Li A; Putmans P; Malbec L; Hubert C; Lan J; Mies F; Yang Y; Solary E; Daniels DL; Gupta YK; Deplus R; Abdel-Wahab O; Yang YG; Fuks F
    Mol Cell; 2023 Dec; 83(23):4239-4254.e10. PubMed ID: 38065062
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
    Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
    Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SRSF2 directly inhibits intron splicing to suppresses cassette exon inclusion.
    Moon H; Cho S; Loh TJ; Jang HN; Liu Y; Choi N; Oh J; Ha J; Zhou J; Cho S; Kim DE; Ye MB; Zheng X; Shen H
    BMB Rep; 2017 Aug; 50(8):423-428. PubMed ID: 28712387
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia.
    Federmann B; Abele M; Rosero Cuesta DS; Vogel W; Boiocchi L; Kanz L; Quintanilla-Martinez L; Orazi A; Bonzheim I; Fend F
    Hum Pathol; 2014 Dec; 45(12):2471-9. PubMed ID: 25305095
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation.
    Grimm J; Jentzsch M; Bill M; Backhaus D; Brauer D; Küpper J; Schulz J; Franke GN; Vucinic V; Niederwieser D; Platzbecker U; Schwind S
    Am J Hematol; 2021 Oct; 96(10):1287-1294. PubMed ID: 34289154
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity.
    Pellarin I; Dall'Acqua A; Gambelli A; Pellizzari I; D'Andrea S; Sonego M; Lorenzon I; Schiappacassi M; Belletti B; Baldassarre G
    Oncogene; 2020 May; 39(22):4390-4403. PubMed ID: 32332923
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2023 Jan; 87():100920. PubMed ID: 36216757
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [SRSF2 promotes glioblastoma cell proliferation by inducing alternative splicing of FSP1 and inhibiting ferroptosis].
    Hua D; Zhou XX; Wang Q; Sun CY; Shi CJ; Luo WJ; Jiang ZD; Yu SZ
    Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):430-438. PubMed ID: 38678322
    [No Abstract]   [Full Text] [Related]  

  • 58. Therapeutic targeting of RNA splicing in myelodysplasia.
    Kim YJ; Abdel-Wahab O
    Semin Hematol; 2017 Jul; 54(3):167-173. PubMed ID: 28958291
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.
    Hirabayashi S; Flotho C; Moetter J; Heuser M; Hasle H; Gruhn B; Klingebiel T; Thol F; Schlegelberger B; Baumann I; Strahm B; Stary J; Locatelli F; Zecca M; Bergstraesser E; Dworzak M; van den Heuvel-Eibrink MM; De Moerloose B; Ogawa S; Niemeyer CM; Wlodarski MW;
    Blood; 2012 Mar; 119(11):e96-9. PubMed ID: 22238327
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.
    Patnaik MM; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
    Am J Hematol; 2013 Mar; 88(3):201-6. PubMed ID: 23335386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.